Medicxi, a London, UK- Geneva, Switzerland- and Jersey-based life sciences investment firm, announced its $400m Fund IV.
Medicxi IV will continue to support drug hunters with clear product visions to deliver transformative therapies for patients.
Led by Francesco De Rubertis, Co-founder and Partner, Nick Williams, Partner, and Giovanni Mariggi, Partner, Medicxi is a healthcare-focused investment firm which aims to create and invest in companies across the full drug development continuum. By leveraging a core team of 35 investment and drug development professionals, the firm invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need.
Medicxi’s approach is to create sound connections between pharmaceutical companies and its team of subject matter experts, drug hunters and developers, who act as partners for the innovators in which they are investing.
Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals) and obicetripib (New Amsterdam Pharma). A number of Medicxi assets have been acquired by global pharmaceutical companies, including Villaris Therapeutics (Incyte), MiroBio (Gilead Sciences) and Versanis Bio (Eli Lilly) within the last twelve months.
FinSMEs
27/06/2023